Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes

S. Michael Deatley, Michael Y. Aksenov, Marina V. Aksenova, Bart Harris, Robert Hadley, Pamela Cole Harper, John M. Carney, D. Allan Butterfield

Research output: Contribution to journalArticlepeer-review

75 Scopus citations


Adriamycin (ADM) is a broad-spectrum antineoplastic antibiotic used to treat cancer patients. However, the usefulness of this drug is presently limited by the development of a dose-dependent cardiotoxicity. A current hypothesis for the ADM-induced cardiotoxicity is the production of reactive oxygen radicals by the drug. We utilized the fluorescent indicator 2',7'-dichlorodihydrofluorescein diacetate (DCFH/DA), in which fluorescence appears if reactive oxygen species (ROS) are present, to investigate the ability of ADM to generate reactive oxygen species and the potential protective effect of antioxidants in a cultured cardiomyocyte model. All three of the antioxidants (alpha-phenyl-tert-butyl nitrone (PBN), trolox, and 5-aminosalicyclic acid (5-ASA)) tested in our ADM-treated myocytes provided protection against the oxidative stress induced by the drug. These findings suggest that antioxidants modulate ADM-induced oxidative stress, and they are discussed in terms of a possible therapeutic strategy in the prevention of cardiotoxicity resulting from ADM administration. Copyright (C) 1999.

Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalCancer Letters
Issue number1
StatePublished - Feb 8 1999

Bibliographical note

Funding Information:
This work was supported in part by grants from the NIH and from Centaur Pharmaceuticals, Inc.


  • Adriamycin
  • Antioxidants
  • Cardiotoxicity
  • Free radicals

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes'. Together they form a unique fingerprint.

Cite this